Paper Details

  1. Home
  2. Paper Details

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

Author: MundorfT K, ReisB L, SallK, StevensonO D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

CsA 0.05% and 0.1% ophthalmic emulsions were safe and effective in treating moderate to severe dry eye disease.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare the efficacy and safety of cyclosporin A ([CsA] 0.05% and 0.1% ophthalmic emulsions) to vehicle in patients with moderate to severe dry eye disease. DESIGN: Multicenter, randomized, double-masked, parallel-group, 6-month, vehicle-controlled. PARTICIPANTS: A total of 877 patie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0161-6420(99)00176-1

データ提供：米国国立医学図書館（NLM）

A New Oasis: Cyclosporine for Dry Eye Disease

This research explores the arid landscape of dry eye disease, a condition that can cause discomfort and vision problems. The researchers embarked on a journey to evaluate the effectiveness of cyclosporine, a medication commonly used to suppress the immune system, as a potential treatment for dry eye. It was like searching for a new source of water in a parched desert, hoping to alleviate the dryness and irritation.

A Refreshing Discovery

The study found that cyclosporine ophthalmic emulsions were safe and effective in treating moderate to severe dry eye disease, significantly improving both objective and subjective measures. This was like discovering a refreshing oasis in the desert, providing relief from the dryness and discomfort. The results show that cyclosporine can improve corneal and interpalpebral dye staining, tear production, and overall symptoms of dry eye. It's a promising discovery that could help countless individuals who struggle with this condition.

Navigating the Desert of Dry Eye

This research offers a valuable new treatment option for dry eye disease, providing hope for individuals seeking relief from its uncomfortable symptoms. It's a reminder that even in the seemingly barren desert of eye conditions, there is always the possibility of finding new solutions. It's crucial to consult an ophthalmologist for a proper diagnosis and personalized treatment plan. We need to keep searching for new oases of knowledge to improve the lives of those affected by dry eye disease.

Dr. Camel's Conclusion

This study demonstrates the efficacy and safety of cyclosporine ophthalmic emulsions in treating moderate to severe dry eye disease. It presents a promising new treatment option, offering hope and relief for those who struggle with this condition. The research emphasizes the importance of exploring new therapies and continuously expanding our knowledge to address the diverse challenges of eye health.
Date :
  1. Date Completed 2000-04-18
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

10768324

DOI: Digital Object Identifier

10.1016/s0161-6420(99)00176-1

Related Literature

Article Analysis
・Effects of cyclosporine ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.